Here, we describe a bispecific construct for the treatment of RA by combining a well-established anti-TNF therapeutic domain [single-chain variable fragment (scFv)-adalimumab, HumiraTM, AbbVie Inc. North Chicago, IL, USA] with a tissue-targeting domain we previously described (scFv-A7) (10). The gene discussed is TNF; the disease is rheumatoid arthritis.